Once-monthly subcutaneous olanzapine LAI requires no loading doses, oral supplementation, or post-injection monitoring, based on phase 3 SOLARIS data.
|Slideshows|July 4, 2018
- Vol 35, Issue 7
- Volume 35
- Issue 7
Silver Linings After Abuse and Neglect
Author(s)Brian Miller, MD, PhD, MPH
The neuroprotective role of resilience in patients with schizophrenia who experienced early childhood trauma is evaluated in this brief update.
Advertisement
Articles in this issue
about 8 years ago
Major Depressive Episode: Is It Bipolar I or Unipolar Depression?about 8 years ago
Addressing Depression: The World’s Largest Health Problemabout 8 years ago
Psychotherapeutic Interventions for Depression: Which Work Best?about 8 years ago
Multimodal Markers and Biomarkers of Treatmentabout 8 years ago
A Historical Perspective on Suicideabout 8 years ago
10 Meditations on Succeeding—and Flourishingabout 8 years ago
Babble on Revisitedabout 8 years ago
Millard Salter’s Last DayAdvertisement
Related to this article
Neurosterix advances NTX-253, an oral M4 PAM, into phase 2 for schizophrenia after phase 1 shows promising safety and pharmacokinetics.
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
Blinding, Ethics, and Safety Safeguards in Psychedelic Clinical Research
4
Should Postpartum Psychosis Be Included in the DSM?
5